ANNUAL REPORT 2020

Oversight

The Breast Cancer Clinical Research Unit (BCCRU) focuses on the translational interface of therapeutic development. Breast cancer is a heterogeneous disease, and thus, there are large inter-patient variations in terms of disease course, prognosis, relapse and resistance to conventional or targeted therapies. Our activities are directed towards personalised treatment and range from preclinical models to correlative studies and clinical trials. Specifically, our research areas cover the:

- Study of the mechanisms of resistance against CDK inhibitors.
- Role of FGFR1 in cancer progression and therapeutic resistance in hormone-positive cancer.
- Characterisation of aberrant signalling axes in triple-negative breast cancer.
- Study of the implications of hypoxia in response to immunotherapy.

"We have provided clinical proof-of-concept of the synergy between antiangiogenics and mitochondrial inhibitors in breast cancer, which we previously described in animal models."